Extraordinary potency of a novel delta opioid receptor agonist is due in part to increased efficacy

Life Sciences

Volumn 61, Issue 2, 1997, Pages 129-135

  Kramer, Thomas H ^a   Bartosz Bechowski, Hubert ^b   Davis, Peg ^b   Hruby, Victor J ^b   Porreca, Frank ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Agonist efficacy; Bioassay; Delta opioid receptors; Vas deferens

Indexed keywords

CHLORNALTREXAMINE; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DELTA OPIATE RECEPTOR ANTAGONIST; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINETHREONYLAMIDE; ENKEPHALIN DERIVATIVE; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; MU OPIATE RECEPTOR ANTAGONIST; NALOXONE; NALTRINDOLE; NORBINALTORPHIMINE; OPIATE PEPTIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; MALE; MOUSE; NONHUMAN; RECEPTOR AFFINITY; RECEPTOR INTRINSIC ACTIVITY; SIGNAL TRANSDUCTION; VAS DEFERENS;

ANIMALS; BIOLOGICAL ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; MALE; MICE; MICE, INBRED ICR; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDES; PEPTIDES, CYCLIC; RECEPTORS, OPIOID, DELTA; VAS DEFERENS;

ANIMALIA;

EID: 0030969093     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00367-6     Document Type: Article

References (20)

1. T.H. KRAMER, P. DAVIS, V.J. HRUBY, T.F. BURKS AND F. PORRECA, J. Pharmacol. Exp. Ther. 266 577-584 (1993).
2. H. BARTOSZ-BECHOWSKI, P. DAVIS, T. ZALEWSKA, J. SLANINOVA, F. PORRECA, H.I. YAMAMURA AND V.J. HRUBY, J. Med. Chem. 37 146-150 (1994).
3. T.H. KRAMER, J.E. SHOOK, W. KAZMIERSKI, E.A. AYRES, W.S. WIRE, V.J. HRUBY AND T.F. BURKS, J. Pharmacol. Exp. Ther. 249 544-551 (1989).
4. P.S. PORTOGHESE, A.W. LIPKOWSKI AND A.E. TAKEMORI, Life Sci. 40 1287-1292 (1987).
5. P.S. PORTOGHESE, M. SULTANA AND A.E. TAKEMORI, Eur. J. Pharmacol. 146 185-186 (1988).
6. R.F. FURCHGOTT AND P. BURSZTYN, Ann. N. Y. Acad. Sci. 144 882-893 (1967).
7. P.S. PORTOGHESE, D.L. LARSON, J.B. JIANG, A.E. TAKEMORI AND T.P. CARUSO, J. Med. Chem. 21 598-599 (1978).
8. R. COTTON, M.G. GILES, L. MILLER, J.S. SHAW AND D. TIMMS, Eur. J. Pharmacol. 97 331-332 (1984).
9. O. ARUNLAKSHANA AND H.O. SCHILD, Br. J. Pharmacol. 14 48-58 (1959).
10. J.W. BLACK AND P. LEFF, Proc. R. Soc. Lond. 220 141-162 (1983).
11. D.Z. D'ARGENIO AND A. SCHUMITZKY, Computer Programs in Biomedicine 9 115-134 (1979).
12. D.Z. D'ARGENIO AND A. SCHUMITZKY. ADAPT II User's Guide, p.23, Los Angeles, CA, Biomedical Simulations Resource, USC (1992).
13. S.J. WARD, P.S. PORTOGHESE AND A.E. TAKEMORI, Eur. J. Pharmacol. 80 377-384 (1982).
14. T.P. KENAKIN, Trends Pharmacol. Sci. 10 18-22 (1989).
15. D. COLQUHOUN, Trends Pharmacol. Sci. 10 17(1989).
16. L. FANG, R.J. KNAPP, R. HORVATH, T.O. MATSUNAGA, R.C. HAASETH, V.J. HRUBY, F. PORRECA AND H.I. YAMAMURA, J. Pharmacol. Exp. Ther. 268 836-846 (1994).
17. P. LEFF AND I.G. DOUGALL, Br. J. Pharmacol. 96 702-706 (1989).
18. P.L. PRATHER, H.H. LOH AND P.Y. LAW, Molec. Pharmacol. 45 997-1003 (1994).
19. S.C. ROERIG, H.H. LOH AND P.Y. LAW, Molec. Pharmacol. 41 822-831 (1992).
20. K.S. LAUGWITZ, S. OFFERMANNS, K. SPINCHER AND G. SCHULTZ, Neuron 10 233-242 (1993).